This is the authors' abstract. We don't add key points for this paper.
The efficacy of new antibiotics for the treatment of community-acquired pneumonia (CAP) typically has been compared with that of established antibiotics in noninferiority clinical trials. However, the US Food and Drug Administration (FDA) is reevaluating the appropriateness of a noninferiority trial design for CAP. The resulting regulatory uncertainty about appropriate trial design has contributed to uncertainty among industry sponsors of new antibiotics. The Infectious Diseases Society of America (IDSA) and its Antimicrobial Availability Task Force (AATF), as well as the FDA, recognized that clarity and consensus on appropriate trial designs for CAP were needed to reverse the trend of reduced investments in the development of new antibacterial agents. To this end, on 17–18 January 2008, the IDSA and the FDA jointly sponsored a workshop on the appropriate design of clinical trials of antibiotics for the treatment of CAP, to provide a forum for scientific discussion. An exhaustive review of available, pertinent data confirms that there is an unequivocal and substantial treatment effect of antibiotic therapy for CAP. The evidence supporting a treatment effect of antibiotics for CAP includes the following: 1. Far higher mortality rates among patients with CAP, regardless of disease severity or age, in the preantibiotic era 2. An immediate decline in the mortality due to CAP for all age groups and disease severity categories within 1 year after the initiation of use of sulfa drugs for the treatment of CAP 3. Without exception, lower mortality rates with antibiotic treatment versus no specific therapy in every clinical trial for CAP 4. Higher rates of treatment failure among patients infected with organisms that are highly resistant to fluoroquinolones or macrolides 5. More treatment failures and increased mortality among patients who received delayed antibiotic therapy 6. A strong correlation between antibiotic exposure and clinical success rates 7. High rates of treatment failure among patients with CAP treated with daptomycin, an antibiotic that was found to be partially inactivated by surfactant, compared with rates among patients given effective antibiotic therapy in randomized, double-blinded, registration-quality studies. 8. Extensive evidence of more-rapid clinical improvement among patients with CAP treated with antibiotics, compared with placebo or no specific therapy. In addition to mortality benefits, studies consistently demonstrate a treatment effect of antibiotics on time to resolution of fever, cough, chest pain, dyspnea, and malaise, and/or shortened duration of hospitalization. The magnitude of the antibiotic treatment effect for clinical response at 72 h after initiation of therapy among patients with CAP ranged from 35% to 95%, depending on disease severity and etiological agent. On the basis of the reviewed data, the IDSA supports and encourages the following design features for registration trials for CAP: a. A noninferiority design, with the of noninferiority by the specific and the severity of pneumonia among the patients in in the of noninferiority for clinical trials of for community-acquired of the following to and of the and to clinical clinical trial and regulatory a. pneumonia severity or a for or of disease of or or the use of in patients to to or of to or of to for specific by the use of of The of this be in the of noninferiority for trials. The following are in the of a noninferiority trials patients with CAP a mortality trials in patients with CAP or CAP are or of patients with mortality as the in a or as a with that to be by In a be by or In a mortality and be by at time resolution of fever, cough, pain, dyspnea, or is a trial of or of to or The uncertainty about designs for clinical trials for CAP is to in the and development of new drugs for treatment of CAP. be by the and of and for clinical trials of new antibacterial for the treatment of CAP. CAP is a of and mortality in the and the to of CAP year in the resulting in and of of The of CAP to the US there is to antibiotics among with a for new antibiotics In clinical trials of new antibiotics for CAP the that the new drugs were to established antibiotics by a noninferiority clinical The FDA has a of the appropriateness of a noninferiority trial design for CAP. The resulting regulatory uncertainty about appropriate trial design has contributed to uncertainty among industry In industry uncertainty about regulatory has the for antibiotic and development The IDSA and its as well as the FDA, recognized that clarity and consensus on appropriate trial designs for CAP were needed to reverse the trend of reduced in development of new antibacterial agents. To this end, on 17–18 January 2008, the IDSA and FDA jointly sponsored a workshop on the appropriate design of clinical trials of antibiotics for the treatment of CAP. The workshop was to from and the FDA to pertinent is on the data and at the and in this are of the IDSA and its is no to the of industry or the The of the IDSA is to the data and the of specific of clinical trial design for CAP are the basis of of noninferiority versus trials for CAP, severity of for the basis of of for noninferiority the of of the etiological appropriate clinical trial and and trial design reviewed registration clinical trials of antibiotics for CAP. is a of treatment effect all trials and all with an clinical response in and of clinical trials of antibiotic therapy for CAP found no in mortality or clinical regardless of treatment versus or duration of therapy In clinical trials clinical response rates among patients with CAP treated with a or compared with rates among patients given treatment with a with or a However, the trial was and the of patients in the were treated with of or versus with or found no in response of or versus to of the fluoroquinolones the of clinical trials of antibiotics for CAP to of new to the antibiotic In of the of clinical success and mortality for patients with CAP treated with antibiotics, of of a new an is an trial for CAP a of to efficacy for an The of a trial was at the a trial a of antibiotic treatment effect However, a trial is there is between the of the treatment or the of treatment to A of at the all the that is to use a placebo for a trial for CAP, on the basis of the to the to the placebo was that the of CAP by were to that pneumonia be treated with antibiotics and that is to a placebo to patients with CAP. workshop that a trial be among with CAP due to an trials been The randomized, trials of CAP in the were with In a trial with CAP who were to treatment with or was the etiological in of the no was in and were the etiological in reduced the time to of chest and resolution of cough, in patients who a of and in patients for no was established The of patients on was lower among patients given treatment with among given in patients with and in the and placebo and in patients for no was established and in the and placebo were in of time to resolution of and time to of chest in patients with and in patients with no In no on the time to of chest or clinical in patients with of on time to resolution of in patients with community-acquired In a trial with CAP due to patients were to treatment with or placebo a time to or was of no compared with the of antibiotics placebo has been in trials patients with is by a trial in a The efficacy of as well as for treatment of CAP by was by from clinical trials US Force In the CAP by was in treated at with or no antibiotics. In the CAP by was in given treatment with or were compared with of patients with the who been given treatment with no antibiotics or In the patients with CAP by were given treatment with or with no antibiotics In all the duration of among patients given treatment with or macrolides was for given treatment with or no antibiotics. in all the shortened duration of patients given treatment with or an of compared with for patients or no A time to resolution of chest was in patients given treatment with a or a The of the trial this was in the was found that and reduced the of and was to In addition to trials for CAP, of are to to patients in trials. review are to at given the of and the efficacy of antibiotics. patients with CAP are to for a trial in be to are to treatment trials and with CAP to on noninferiority trials are appropriate a has been established to be to placebo for treatment of the disease in evidence of to the clinical in the efficacy of the was established be to the noninferiority trial To data that demonstrate evidence of to effect and the of the studies from the of antibiotic use for the treatment of CAP. the studies were that compared the effect of antibiotics with that of no therapy for patients with CAP of studies compared the for patients given treatment with antibiotics with the of patients the of antibiotics. to studies as studies. The studies patients to antibiotic treatment and patients who received no specific antibiotic therapy. to studies as studies. to the 1 and studies were for a of studies that compared antibiotic treatment with no treatment for CAP In studies were that and the efficacy of antibiotics in CAP. The studies are by and studies in mortality among patients with community-acquired The studies were in the by of treatment by and by of were The studies patients with CAP by In the studies all patients of as the etiological patients with the or patients In the the mortality was antibiotic treatment and with antibiotic a in mortality with antibiotic therapy In the the mortality was antibiotics and with antibiotics, an in mortality of with antibiotics. studies established the efficacy of antibiotics for treatment of CAP, CAP that are to be by and the of trials for this of the data by age efficacy of antibiotics for treatment of CAP a of and and reviewed the mortality among patients with CAP by in the preantibiotic era and the by age and the or of mortality was lower among in among the of patients with pneumonia be to on the basis of studies and a and patients and with CAP, who were mortality rates of in the preantibiotic era is higher the mortality for patients in the antibiotic era mortality rates among patients with to age or of the severity of In the of a trial of therapy among patients with CAP by was therapy or and patients therapy an in mortality of to patients who were in a mortality of with no compared with a mortality among patients in and a mortality among patients in at CAP and the mortality with no treatment was higher that with antibiotics in the era In and patients with CAP to sulfa treatment or no specific therapy. the were to on the basis of no was for the The that sulfa treatment a in mortality among patients a among patients and a among patients compared the mortality among patients with pneumonia treated with sulfa drugs in compared with that among patients given no therapy in The that antibiotics treatment for all age regardless of was The treatment effect was for patients and However, among patients the mortality from to with antibiotic for patients and an mortality among compared with a mortality among patients given antibiotics. In all the studies the of antibiotics were for patients with disease for patients with an in mortality of among patients with CAP, an among patients and an among rates were by and and and of from all studies that the mortality among treated versus patients by age specific of in mortality be for age patients and the in mortality among patients given treatment with antibiotics was and the mortality rates among treated patients in age strong to the mortality rates among patients given antibiotic treatment and by the in data of the of age on mortality rates among patients given antibiotic on the basis of and data data a in mortality as a of antibiotic for treatment of CAP and provide of efficacy that be as the basis for noninferiority in CAP trials. the mortality rates among in data the mortality rates among patients specific in data evidence that the is for noninferiority trials for CAP. the studies on CAP by of patients were in all the trials. to the data are studies of the of antibiotic therapy in the of therapy use of an antibiotic the etiological is to in delayed initiation of therapy versus more-rapid initiation of and exposure to an as a of or in therapy. In to macrolides and fluoroquinolones is with clinical failure and increased mortality among patients with CAP initiation of therapy. A in the initiation of antibiotic therapy is with a higher mortality among patients with CAP A reduced mortality with initiation of antibiotics is for patients with disease and disease in by data from studies and patients with CAP demonstrate that for antibiotics fluoroquinolones or with clinical lower are with a in clinical response among patients with CAP, compared with higher In a trial of antibiotic efficacy for of lower clinical to CAP of patients with antibiotic of to CAP, compared with 35% of patients with antibiotic as by and patients with CAP by are at higher of to CAP are given effective antibiotic therapy are given effective antibiotic therapy. In data from clinical trials demonstrate a treatment effect of antibiotics In the a patients with CAP in was in were to or the patients in the of as the etiological agent. was after the of the trial that is inactivated by and in that in the trial was and the were with of the the there were as clinical failures in the in the resulting in a of among the versus among the to the patients in the who of a as the of CAP, the clinical response rates in the treatment compared with the treatment regardless of of the etiological and for a of disease severity antibiotic therapy was to a partially inactivated by In in the era data that are in with data that antibiotics are effective no treatment for CAP. A by in the of CAP, clinical improvement and were 72 is with data from a in a by The of patients with CAP who patients all in an era no effective therapy was available, a for on that by with CAP. of patients with CAP in this by of and by 3. and that the time of of and the time to of in patients with CAP. In after the of antibiotics, clinical trials found to resolution of and of found in the preantibiotic In after of patients with CAP, that of patients with CAP treated with sulfa drugs by of and of patients by 3. that of with CAP treated with antibiotics by of in a trial of sulfa therapy versus no treatment for patients with CAP, of patients sulfa drugs by compared with of patients given no treatment that of patients with CAP a of and chest pain, cough, by 72 h after initiation of antibiotic therapy. data after the of sulfa drugs that antibiotic treatment reduced the time to and/or clinical improvement of CAP. data are with from the trials of or macrolides versus placebo for CAP in in the time to and clinical response rates were for patients antibiotics for placebo In the of antibiotics to an for the treatment of CAP has been by use of time to resolution of and of for was to in resolution of and improvement of a of clinical by of compared with a for of In treatment to in a higher of patients on of antibiotic time to resolution of clinical cough, dyspnea, and chest and a shortened compared with treatment with with or in patients in were time to clinical improvement is a and be to trials that the of severity of CAP. all the data reviewed a treatment effect of antibiotics versus placebo in time to time to clinical response and of The antibiotic treatment effect for or clinical response at 72 h after initiation of therapy in patients with CAP from 35% to 95%, depending on disease severity and etiological agent. In the evidence supporting a treatment effect of antibiotics for CAP includes the following: 1. Far higher mortality rates among patients with CAP, regardless of disease severity or age, in the preantibiotic era 2. An immediate decline in the mortality due to CAP for all age groups and disease severity categories within 1 year after the initiation of use of sulfa drugs for the treatment of CAP 3. Without exception, lower mortality rates with antibiotic treatment versus with no specific therapy in every clinical trial for CAP 4. Higher rates of treatment failure among patients infected with organisms that are highly resistant to fluoroquinolones or macrolides 5. More treatment failures and increased mortality among patients who received delayed antibiotic therapy 6. A strong correlation between antibiotic exposure and clinical success rates 7. High rates of treatment failure among patients with CAP treated with daptomycin, an antibiotic that was found to be partially inactivated by surfactant, compared with rates among patients given effective antibiotic therapy in randomized, double-blinded, registration-quality studies 8. Extensive evidence of more-rapid clinical improvement among patients with CAP treated with antibiotics, compared with placebo or no specific therapy. to the in or noninferiority trials be to that in studies be in by patients with use of a of disease The for CAP are the as and the or and age the of the disease severity in a CAP clinical there are of the of the and as the with antibiotic among patients in and data use of the of that the of noninferiority trials. the disease severity categories the the is is the in patients by severity of the a of age, the age to or the of the mortality rates increased from to to to to as the increased from to the in mortality between and and the between and as there is a correlation between mortality rates among treated patients in the data and the mortality rates for and in the the studies of CAP due to were patients with disease the disease severity of patients in clinical trials be by as and In this trials that patients disease categories are as patients with disease disease or disease are data provide evidence of antibiotic efficacy for disease categories The the for of with disease the all to disease severity In clinical the to the of CAP on the basis of for in the CAP with or with a of be in who to be in be in the of to the of disease as to the of the the are for the be for the clinical trial the is for use in and is needed to for in trials of CAP. there is evidence of a mortality of antibiotic treatment for CAP. The effect is an in mortality of for CAP due to and for all patients with CAP data mortality among patients given antibiotic treatment of and with CAP disease to and to the for a noninferiority trial be the effect that the be to compared with placebo in the of the in the the lower of the noninferiority in a clinical trial for a new antibiotic is in on the basis of the lower of efficacy for the the the noninferiority be that by the effect of the of in that effect of the was the data noninferiority trials for CAP with an of mortality and a noninferiority of depending on the severity of disease among the are on the lower of the of effect in data the to a effect for patients who a higher of data use of a noninferiority trial design to time to resolution of clinical as and cough, or resolution of clinical as a for patients with the of CAP from to is that resolution of fever, cough, chest pain, dyspnea, malaise, or are clinical resolution is to time to and patients substantial and clinical trials that of and resolution of be to is to a from to antibiotic therapy and/or is to a with CAP studies the between time to and/or clinical improvement and time to use of clinical improvement to about the from to antibiotics and has been on the treatment of CAP the treatment effect of antibiotics for clinical is compared with no treatment or and the treatment effect is on clinical and/or the with the noninferiority is for trials is a noninferiority for a of at of treatment is is the treatment and is to a substantial treatment to that as a for for noninferiority in clinical trial However, the from trial to of specific be for specific trial design, the and of the effect and/or the appropriate noninferiority A of the workshop was the of of the of pneumonia in patients in clinical trials. is to the of pneumonia to and effective therapy for CAP in clinical is to for a noninferiority trial for CAP. The data that a mortality of antibiotic therapy for CAP are in from trials that for patients with CAP by for noninferiority trials mortality as an be to the for patients with CAP by However, as there is substantial evidence of a treatment for patients with or pneumonia of as well as for patients with in clinical the etiological antibiotic therapy for CAP. of the to patients who are to an by a specific appropriate for be in be and the to patients to of the in a CAP trial for patients infected with is that the the of the the the of clinical and reduced by to antibiotics, and of CAP, with the of are to to In a of the to from the the trial from of the the trial from the of versus the In in a noninferiority of the to from the the trial of the the trial the of no between the for patients infected with patients to from antibiotic of the in a noninferiority and and reviewed in the of the in the of CAP. of of an for a is and of and in in a the is available, is to in a The of by an of a of to the specific of CAP. In are at the of and be in clinical trials. However, to the that provide from in the clinical trials that been to effect for the the of on the and be a noninferiority for an trial is are and be and of and and and be by with A of or of or in the appropriate clinical with an chest with or is to patients with or for the of pneumonia is well a of the in the trial by and the and clinical of for of CAP between and and be to in age groups In with the in noninferiority trials for CAP the of the trials to the noninferiority mortality and/or clinical as or as be time to or at a specific time resolution of fever, cough, dyspnea, chest pain, malaise, or as well as duration of hospitalization. is as an that the and of the of be of the use of be the of the duration of to the is for a a or is to In a trial design, there is no to with of a for a trial be the of the and evidence to the of the is that be for trials. and compared with time to from the of of and as an is to of for to the of is in of data and of pneumonia demonstrate that among patients with CAP typically within the after after are due to is that the mortality to all within after after A is a to a and well on the is by the by the with no of the by the An of is that a that and a that be by is for the use of to clinical in the of a is be and the be to from the In the of CAP, clinical of as fever, are and for An is a for and by to from of CAP or that a as to a clinical trials by from patients who a of the of a of by clinical trials demonstrate that antibiotics be from patients with who of patients with pneumonia from or the the and the in the of the are appropriate for a clinical of the about However, are that the is and are is with the the of is be for a CAP clinical trial of noninferiority and in the of a and the be a noninferiority of noninferiority was with the the be a of time to time to clinical improvement as a time to and the use of a trial on a noninferiority in is the of are is to be in a clinical the of the be in the trial initiation of the and be or be the and/or to a mortality be time to from clinical the of at in the in a trial that mortality and clinical mortality be the patients are for of the clinical the the trial is the and in the no be In the the be as in the CAP in in addition to is to the efficacy of antibiotics at mortality and due to CAP. in a of be evidence be that that antibiotics the severity of the of the On the basis of a for a noninferiority CAP trial mortality and clinical as or cough, pain, and of by However, use of a has the to mortality the efficacy of the new antibiotic is by a is a of mortality be to the mortality effect is or with the and the of the be appropriate for CAP trials patients with or CAP, with or of patients with CAP in the However, antibiotics a in mortality among patients with CAP of noninferiority with to mortality for new at this the for trials that patients with CAP is In trials that CAP that are patients with CAP, a mortality in this to with the that the trial be to a on this from the In the patients in CAP trials were from the received therapy for an of of the that patients who within that time were to been to from antibiotic therapy. However, in of therapy and is that this is in patients therapy an of of the trial or by of data be from the is that the for the efficacy of all be a of all in the design, and of clinical trials for CAP The of or is a of this to CAP a of as of the and antibiotic has the to the of be and to the for and to be on an basis with use of all patients in the the and of includes the of trial on efficacy in a clinical trial to increased and To the of for the new antibiotic be a in this the of the of antibiotic therapy antibiotics given as a of the trial the trial the of antibiotic and and data and are to a treatment or studies for that were in and studies design to of the and all trial who are with in the be CAP clinical trials a design antibiotics are with or from of the trial or therapy is in of resistant or of a substantial of in use of an trial or to provide the However, the development of specific in patients to treatment of clinical of the or of a from the trial development of initiation of a of and antibiotic that are the of CAP clinical trials. antibiotic therapy. The in and patients clinical trials are that within a after is delayed initiation of therapy for patients with CAP, as well as for and for with of clinical to for a of antibiotics or of antibiotic therapy to patients of antibiotics is an to the of the antibiotic about trial The of CAP in that in of and to the of clinical trial design for of the increased of in CAP, and in the evidence of antibiotic for patients with CAP is to noninferiority trials. are by and in this The following and are of the The IDSA for patients and The are by for IDSA about the of of antibiotic development and rates of antibiotic among and that patients new drugs for treatment of CAP to be in the and development on to development of a new is that the be to a or from An to the and development of new antibiotics is of FDA for clinical trials of antibacterial for CAP. An exhaustive review of available, pertinent data confirms that there is an unequivocal and substantial treatment effect of antibiotic therapy for CAP. therapy in a in mortality among patients with CAP and an in mortality among patients with CAP by antibiotic therapy improvement in clinical of among patients with CAP the evidence of to is for use of noninferiority trials of antibiotics for the treatment of CAP of all the correlation of mortality rates of patients given antibiotic treatment in CAP trials and of data the needed for noninferiority trials of CAP. the data, the of trials of antibiotics for CAP is The IDSA a and of FDA to industry on the design for registration clinical trials for CAP. On the basis of the reviewed data, the IDSA supports and encourages the following design A noninferiority design, with the of noninferiority by the specific and the severity of pneumonia among the as in 5. of the following to and of the and to clinical clinical trial and regulatory or a for or of disease
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
A 2008 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: